The mutual effects on safety and immunogenicity of combined vaccination with 15-valent pneumococcal conjugate vaccine and adsorbed acellular DPT in 3-month healthy infants: A randomized, open-label, controlled, phase III clinical trial.
Hum Vaccin ImmunotherAug 3, 2026 (epub)
Pan Lu-Lu, Mu Hong-Ze, Gao Zhao et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III randomized controlled trial assessed the safety and immunogenicity of coadministering the 15-valent pneumococcal conjugate vaccine (PCV15) with the DTaP vaccine in 1110 healthy infants aged 3 months. The results indicated that the seroconversion rates and geometric mean concentrations (GMCs) of DTaP in the coadministration group were non-inferior to those in the DTaP alone group, with a lower incidence of adverse events in the coadministration group.
Key findings
- Seroconversion rates and GMCs of DTaP in the P+DTP group were non-inferior to the DTaP group.
- The incidence of adverse events in the P+DTP group was lower than in the P-DTP group.
- No significant difference in IgG antibody positivity rate between P+DTP and P-DTP groups.
Why it matters
Understanding the safety and immunogenicity of combined vaccinations is crucial for optimizing immunization schedules in infants, potentially improving vaccine uptake and public health outcomes.